Intravenous clomipramine challenge in obsessive-compulsive disorder: predicting response to oral therapy at eight weeks

• Published in: Biological psychiatry (1969) Vol. 44; no. 3; pp. 220 - 227
• Main Authors: Sallee, Floyd R, Koran, Lorrin M, Pallanti, Stefano, Carson, Stanley W, Sethuraman, Gopalan
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.08.1998; Elsevier Science
• Subjects: Administration, Oral; Adolescent; Adult; Affect - drug effects; Biological and medical sciences; Clomipramine; Clomipramine - administration & dosage; Double-Blind Method; Drug Administration Schedule; Female; Human Growth Hormone - blood; Humans; Hydrocortisone - blood; Infusions, Intravenous; intravenous; Male; Medical sciences; Neuropharmacology; Obsessive-Compulsive Disorder - diagnosis; Obsessive-Compulsive Disorder - drug therapy; OCD; Pharmacology. Drug treatments; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psychology. Psychoanalysis. Psychiatry; Psychopharmacology; Serotonin Uptake Inhibitors - administration & dosage; Treatment Outcome; Clomipramine; OCD; intravenous; Human; Obsessive compulsive disorder; Intravenous administration; Serotonin; Psychotropic; Treatment efficiency; Anxiety disorder; Prediction; Tricyclic compound; Neurotransmitter; Antidepressant agent; Pretreatment
• ISSN: 0006-3223; 1873-2402
• DOI: 10.1016/S0006-3223(97)00373-9

Background: Challenge with intravenous clomipramine (CMI) is serotonin selective and has been reported to transiently exacerbate symptoms in obsessive-compulsive disorder (OCD) patients, and to predict subsequent response to oral CMI therapy. Methods: We administered CMI (12.5 mg, IV) to medication free OCD patients ( N = 29) and normal controls ( N = 22) to characterize neurohormonal response. A subset of OCD patients (26/29), was then treated with either pulse load IV or oral CMI followed by 8 weeks of oral CMI therapy. Results: In response to CMI challenge, OCD patients exhibit blunted cortisol and exaggerated growth hormone response relative to normal controls. OCD patients differ from controls in “sadness” ratings, with controls exhibiting increased dysphoria in response to CMI. Growth hormone response to CMI challenge predicts treatment response (≥ 25% ↓ YBOCS from baseline) to oral CMI at 8 weeks. Conclusions: Growth hormone abnormalities associated with OCD in response to CMI challenge differentiates nonresponders after 8 weeks of oral CMI treatment from responders.